Thieler Law Corp, member of the Investor Attorney Network, is investigating whether members of the board of directors of Cambrex Corporation (NYSE: CBM) acted responsibly on behalf of investors’ profitability in the planned $2.4 billion sale to an affiliate of the Permira Funds.

On August 07, 2019, Cambrex Corporation (NYSE: CBM) announced that they had entered into a merger agreement. Under the terms of the merger agreement, Cambrex shareholders will receive only $60.00 in cash each share of Cambrex stock they own. 

Based in East Rutherford, New Jersey, and founded in 1981 Cambrex Corporation provides various products and services for the development and commercialization of new and generic therapeutics worldwide.

The investigation focuses on whether NYSE: CBM investors received the highest price and whether the directors of Cambrex Corporation acted in the best interest of Cambrex Corporation company and its shareholders.   

If you purchased Cambrex Corporation (NYSE: CBM) prior to August 07, 2019, you should contact Thieler Law Corp at mail@thielerlaw.com or call +1 (619) 377 - 4324.

Thieler Law Corp purchases advertisements on search engines, social media sites and other websites. If you send us information, note that does not create an attorney-client relationship with the firm. Materials are provided for informational purposes only and do not constitute legal advice. We are only licensed to practice law in Germany. We are neither licensed nor qualified to render advice on US Federal or State law.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185